US Patent 8,895,612: Scope, Claims, Expiration, Orange Book Position, and Iron-Deficiency Patent Landscape
US Patent 8,895,612 protects rapid administration of high-dose iron carbohydrate complexes for treating iron deficiency and related conditions. The broadest claim requires a single dose containing at least approximately 0.6 grams of elemental iron, administration in approximately 15 minutes or less, and a substantially non-immunogenic carbohydrate component. The patent is most commercially relevant to ferric carboxymaltose products, including Injectafer, although product coverage depends on the exact complex, dose, infusion time, formulation, and listed patent rights.
The patent does not claim ferric carboxymaltose as a composition alone. Its principal protection is a method-of-treatment combination requiring a specified iron complex, high elemental-iron dose, rapid administration, and immunological characteristics.
What does US Patent 8,895,612 protect?
US Patent 8,895,612 protects methods for treating iron deficiency or dysfunctional iron metabolism by rapidly administering a high-dose iron carbohydrate complex.
Claim 1 requires all of the following:
| Claim limitation |
Requirement |
| Therapeutic use |
Treatment of a disease, disorder, or condition involving iron deficiency or dysfunctional iron metabolism |
| Patient |
A subject in need of treatment |
| Product |
An iron carbohydrate complex |
| Dose |
At least about 0.6 grams of elemental iron in one dosage unit |
| Administration time |
About 15 minutes or less |
| Complex selection |
One of six specified iron carbohydrate complexes |
| Immunological profile |
A substantially non-immunogenic carbohydrate component |
The six expressly identified complex categories are:
- Iron carboxymaltose
- Iron mannitol
- Iron polyisomaltose
- Iron polymaltose
- Iron sorbitol
- Iron polyglucose sorbitol carboxymethyl ether
The claim is cumulative. A product generally must satisfy every limitation of claim 1 to fall within its literal scope. A ferric carboxymaltose product administered over more than 15 minutes, for example, may not satisfy the independent claim even if it contains more than 600 mg of elemental iron.
The patent was issued on November 25, 2014. The relevant patent term appears to extend into 2027, subject to the applicable earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any statutory corrections. The patent record and FDA listing should be reviewed together for a definitive live-exclusivity determination. [1]
How do the dependent claims expand the patent’s scope?
The dependent claims broaden the commercial situations covered by the patent while adding product, dose, disease, formulation, and administration limitations.
Dose and administration claims
Claims 7 through 10 define higher dose and shorter administration windows:
| Claims |
Limitation |
| Claim 7 |
At least about 1.0 gram of elemental iron |
| Claim 8 |
At least about 1.5 grams |
| Claim 9 |
At least about 2.0 grams |
| Claim 10 |
Administration in about 5 minutes or less |
These claims are important because many commercial intravenous iron regimens use 1,000 mg or larger cumulative treatment doses. The claims do not necessarily require the entire treatment course to be completed in one visit, but they do require the claimed amount to be delivered in a single dosage unit.
A 1,000 mg dose administered over 15 minutes can fall within claim 1 and claim 7. The same dose administered over 20 minutes may fall outside those claims unless another enforceable claim or doctrine applies.
Disease and patient populations
Claims 3 through 6 cover a wide range of iron-deficiency conditions. The claims expressly identify:
- Iron deficiency anemia
- Anemia associated with chronic or acute blood loss
- Pregnancy and childbirth
- Heavy uterine bleeding and menstruation
- Chronic kidney disease and dialysis
- Surgery or acute trauma
- Gastrointestinal bleeding
- Parasitic infection
- Inflammatory and autoimmune diseases
- Cancer and chemotherapy
- Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis
- Poor nutrition or impaired iron absorption
- Restless leg syndrome
- Blood donation
- Hair loss
- Attention deficit disorder
These disease limitations are dependent claims. They do not narrow claim 1 unless the claim is asserted as a dependent claim. Their practical value is greatest where a generic or competing product is used for a specifically claimed indication.
Ferric carboxymaltose claims
Claim 11 narrows the complex to iron carboxymaltose. Claim 12 describes a particular ferric carboxymaltose structure and physical profile, including:
- Approximately 28% elemental iron
- Molecular weight of approximately 150,000 daltons
- A polynuclear iron(III)-hydroxide carboxymaltose structure
- A specified glucopyranosyl and carboxylate arrangement
These limitations are directed toward the type of complex used in ferric carboxymaltose products rather than toward a conventional low-molecular-weight iron salt.
Injectafer, marketed by American Regent in the United States, uses ferric carboxymaltose. Its FDA labeling describes administration of 750 mg intravenously in two doses separated by at least seven days, or a 1,000 mg single-dose regimen for certain adult patients under the applicable label. [2] The labeled administration method and dose are commercially relevant to the patent’s high-dose method claims.
Polyglucose sorbitol carboxymethyl ether claims
Claims 13 and 14 cover an iron polyglucose sorbitol carboxymethyl ether complex, including a polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite complex.
This language is structurally closer to iron oxide or magnetite-based complexes than to ferric carboxymaltose. It may be relevant to historical or non-U.S. products, investigational iron preparations, and products with iron-oxide cores coated with carbohydrate polymers.
Particle-size claims
Claim 15 requires either:
- A mean iron core size of at least approximately 1 nm but no more than approximately 9 nm; or
- A mean particle size for the iron carbohydrate complex of no more than approximately 35 nm.
These limitations introduce a technical infringement issue. Particle size can vary by analytical method, sample preparation, aggregation state, and measurement technique. A patent dispute involving claim 15 would likely require analytical testing, control of measurement methodology, and expert interpretation.
Parenteral administration and dilution
Claims 16 and 17 cover parenteral administration and specify concentration and route alternatives:
| Route |
Claimed administration |
| Intravenous infusion |
Approximately 1,000 mg elemental iron in 200-300 mL of diluent |
| Bolus injection |
Approximately 1,000 mg elemental iron in 200-300 mL of diluent |
| Intramuscular injection |
Approximately 500 mg elemental iron in less than approximately 10 mL of diluent |
The intravenous limitation is commercially significant because many hospital and infusion-center products are administered in diluted intravenous bags. The wording of claim 17 may create a factual dispute over whether the claimed concentration refers to the final administered solution, the product preparation, or the dosing unit.
Repeat administration
Claim 18 covers a second administration after recurrence of at least one symptom. This is a maintenance or retreatment concept. It may apply where the patient receives repeat intravenous iron after recurrent anemia or recurrent symptoms, but it does not eliminate the dose, time, complex, and immunogenicity limitations of claim 1.
Iron-release limitation
Claim 19 requires that the complex does not have an iron-release rate of 115 micrograms per deciliter at a concentration of 2,000 micrograms per deciliter.
This negative limitation may be directed to differentiating the claimed complexes from iron dextran or other complexes with distinct release behavior. Its interpretation may depend on the assay conditions, calibration, pH, temperature, timing, and definition of release rate. It is not a simple label-based limitation and could require laboratory testing.
Polyisomaltose claim
Claim 20 identifies an iron polyisomaltose complex. This language may reach iron derisomaltose or closely related iron-isomaltose nomenclature depending on the chemical identity and claim construction. The distinction between polyisomaltose, iron isomaltoside, and iron derisomaltose is commercially important and cannot be resolved from the product’s trade name alone.
Which commercial iron products are most exposed?
The patent’s greatest potential relevance is to high-dose intravenous iron products administered rapidly in a single treatment unit.
| Product |
Active complex |
Typical U.S. positioning |
Potential relevance |
| Injectafer |
Ferric carboxymaltose |
High-dose IV iron |
Closest fit to claims 1, 7, 11, and 12 |
| Monoferric |
Ferric derisomaltose |
1,000 mg or larger IV dosing |
Potential relevance to polyisomaltose-related claims, subject to chemical identity and timing |
| Feraheme |
Ferumoxytol |
510 mg doses, generally separated by several days |
Often outside the 0.6-gram single-dose threshold |
| Venofer |
Iron sucrose |
Fractionated IV dosing |
Usually outside the single high-dose limitation |
| Ferrlecit |
Sodium ferric gluconate |
Low-dose fractionated IV dosing |
Usually outside claim 1’s dose threshold |
| INFeD |
Iron dextran |
High-dose IV or IM iron |
Potentially excluded by non-immunogenicity and anti-dextran limitations |
| CosmoFer, where marketed |
Low-molecular-weight iron dextran |
High-dose IV iron |
Potentially relevant to dose and timing, but dextran-cross-reactivity issues are material |
The analysis turns on the administered elemental iron dose, not simply the volume of product or the total amount of complex. A 750 mg ferric carboxymaltose dose is above the claim 1 threshold. A 510 mg ferumoxytol dose is below it.
What does “substantially non-immunogenic” mean in the patent?
The non-immunogenicity requirement is a central limitation.
Claim 2 further requires substantially no cross-reactivity with anti-dextran antibodies. This language is significant because conventional iron dextran products can be associated with dextran-related immunological concerns, while ferric carboxymaltose and several other newer complexes were developed to provide high-dose iron without the same dextran antigen profile.
A product assessment would likely examine:
- The chemical identity of the carbohydrate component
- Whether the carbohydrate is structurally related to dextran
- Cross-reactivity assays using anti-dextran antibodies
- Product labeling and regulatory characterization
- The manufacturing process and carbohydrate source
- The analytical method used to establish cross-reactivity
A product can be non-dextran without automatically satisfying every interpretation of “substantially non-immunogenic.” The claim language may require evidence directed to the actual complex and its immunological behavior.
What is the patent term and expiration outlook for US 8,895,612?
The patent issued in 2014 and is associated with a priority chain reaching back to the late 2000s. On that basis, the ordinary 20-year term would place expiration in approximately 2027, subject to the actual earliest effective filing date and any patent-term adjustment.
| Event |
Date or period |
| Earliest priority period |
Late 2000s |
| U.S. patent issue |
November 25, 2014 |
| Expected ordinary term |
Approximately 2027 |
| Regulatory exclusivity |
Separate from patent term |
| Patent listing |
Must be confirmed against the current FDA Orange Book |
Patent expiration does not automatically terminate all protection surrounding a commercial product. Separate composition, formulation, manufacturing, method-of-use, and pediatric-exclusivity rights may have different dates.
What is the Orange Book status of US 8,895,612?
The FDA Orange Book lists patents submitted by an NDA holder for an approved drug product. A patent can be relevant to a product without being listed in the Orange Book, and an Orange Book listing does not establish that every claim covers every use of the product.
For Injectafer, the relevant review should compare:
- The current Orange Book patent table for the NDA.
- The patent use code, if any.
- The patent expiration date reported by FDA.
- Any pediatric-exclusivity extension.
- The approved labeling and dosage regimen.
- The proposed labeling of a generic applicant.
The Orange Book is also the source used by generic applicants to assess Paragraph IV exposure. [3] A precise current listing determination requires the live FDA Orange Book record for the applicable NDA and product presentation.
What Paragraph IV and generic-entry risks does the patent create?
A generic applicant seeking approval for a high-dose ferric carboxymaltose product could address the patent through one or more certifications:
- Paragraph II: The patent has expired.
- Paragraph III: The applicant will not market until patent expiration.
- Paragraph IV: The patent is invalid, unenforceable, or will not be infringed.
- Section viii statement: The proposed labeling carves out the patented use, where permitted.
Potential Paragraph IV positions include:
Non-infringement
A challenger could argue that its product:
- Is administered in more than 15 minutes.
- Contains less than 600 mg elemental iron per dosage unit.
- Does not use one of the claimed complexes.
- Does not have the claimed carbohydrate or particle-size properties.
- Is not administered in the claimed dilution or route.
- Does not satisfy the anti-dextran or non-immunogenicity limitations.
Invalidity
Potential validity arguments could focus on:
- Anticipation by earlier high-dose intravenous iron methods.
- Obviousness based on known iron carbohydrate complexes and infusion protocols.
- Indefiniteness of terms such as “about,” “substantially non-immunogenic,” and “substantially no cross reactivity.”
- Enablement and written-description support for the broad list of complexes, conditions, doses, routes, and administration times.
- Patentable distinction over prior art describing high-dose intravenous iron.
Inducement and label strategy
A generic applicant may attempt to avoid method-of-use liability by excluding a patented indication or administration regimen from its labeling. That strategy is more difficult where the patented method overlaps with the principal approved use and ordinary clinical practice.
The risk is highest for a generic ferric carboxymaltose product labeled for rapid administration of 750 mg or 1,000 mg doses. It is lower for products labeled only for fractionated dosing or longer infusion times.
Are there biosimilar risks?
Traditional biosimilar litigation is generally not the primary pathway for intravenous iron carbohydrate complexes. These products are typically regulated as drug products rather than as biologics under the Public Health Service Act. The relevant competition is therefore more likely to involve abbreviated new drug applications, 505(b)(2) applications, or other small-molecule drug pathways rather than a conventional biosimilar application.
The technical risk remains substantial because iron carbohydrate complexes are complex nanomedicinal products. Regulators and courts may examine:
- Iron-core size and distribution
- Carbohydrate structure
- Molecular-weight distribution
- Iron-release kinetics
- Pharmacodynamic equivalence
- Stability and aggregation
- Immunological behavior
- Batch-to-batch manufacturing consistency
FDA has issued product-specific guidance and regulatory materials for complex iron products, including ferric carboxymaltose and other parenteral iron products. [4]
How strong is the patent estate around ferric carboxymaltose?
US 8,895,612 has meaningful commercial scope but is not a complete composition-of-matter monopoly over ferric carboxymaltose.
Its strengths are:
- Coverage of high-dose administration
- Coverage of rapid infusion
- Explicit ferric carboxymaltose claims
- Broad treatment-condition language
- Parenteral administration claims
- Claims directed to particle size and product characteristics
- Potential overlap with commercially relevant 750 mg and 1,000 mg regimens
Its weaknesses are:
- The broadest claim requires several limitations simultaneously.
- The claim is method-based rather than composition-only.
- “About 15 minutes or less” creates a straightforward design-around opportunity.
- The non-immunogenicity requirement may require proof.
- Some dependent claims contain technically narrow and potentially contestable limitations.
- An applicant may pursue a longer infusion time or lower single-unit dose.
The estate is therefore strongest against a product that copies the commercial dosing pattern closely. It is weaker against a product designed around lower individual doses, longer administration, a different complex, or a carved-out label.
What manufacturing and geographic barriers remain after patent expiration?
Patent expiration will not eliminate all market-entry barriers. Intravenous iron products require specialized manufacturing and characterization capabilities. Important technical barriers include:
- Control of iron-core nucleation and particle-size distribution
- Reproducible carbohydrate coating
- Control of iron release
- Sterile parenteral manufacturing
- Low endotoxin and particulate control
- Stability during storage and dilution
- Demonstration of pharmaceutical equivalence or therapeutic equivalence
- Regulatory characterization of complex mixtures
Geographic rights must also be analyzed separately. US 8,895,612 does not establish protection in Europe, Japan, China, Canada, or other jurisdictions. Foreign counterparts may have different claims, prosecution histories, term dates, and validity outcomes.
What litigation and settlement issues should companies monitor?
The most relevant disputes would involve:
- ANDA Paragraph IV notices for ferric carboxymaltose or derisomaltose products
- Hatch-Waxman litigation concerning rapid high-dose administration
- Claims over Orange Book listing accuracy
- Declaratory-judgment actions by generic applicants
- Settlement agreements that delay generic launch
- Patent-term and pediatric-exclusivity calculations
- Licensing or supply arrangements involving ferric carboxymaltose technology
A litigation review should distinguish between disputes involving the active complex itself and disputes involving administration methods. A settlement resolving a composition patent may not resolve a separate method patent such as US 8,895,612.
Key Takeaways
- US 8,895,612 is primarily a high-dose, rapid-administration method patent.
- Claim 1 requires at least approximately 600 mg elemental iron, administration in approximately 15 minutes or less, one of six specified iron carbohydrate complexes, and a substantially non-immunogenic carbohydrate component.
- Ferric carboxymaltose is the most commercially relevant claimed complex.
- Claims 7 through 10 escalate protection to 1,000 mg, 1,500 mg, 2,000 mg, and administration in five minutes or less.
- The patent may remain relevant through approximately 2027, subject to the verified patent-term record.
- Generic risk is highest for a ferric carboxymaltose product using a 750 mg or 1,000 mg dose administered within the claimed time period.
- Lower-dose, fractionated-dose, longer-infusion, or differently formulated products have stronger design-around positions.
- The patent should be analyzed with the FDA Orange Book, the approved product label, patent-family records, and any Paragraph IV litigation history.
FAQs About US Patent 8,895,612
Does US 8,895,612 cover Injectafer?
It may cover methods using Injectafer’s ferric carboxymaltose when the administered elemental iron dose, administration time, and other claim limitations are satisfied. The patent does not automatically cover every use or administration of Injectafer.
Does the patent cover a 500 mg intravenous iron dose?
A 500 mg dose is below claim 1’s threshold of at least approximately 0.6 grams of elemental iron. It may still be relevant to a dependent claim only if every applicable limitation is satisfied, but the principal independent claim is not met by dose alone.
Does the patent cover Monoferric?
Potentially, depending on whether the product’s iron complex falls within the claim language for iron polyisomaltose or a related complex, and whether the dose, administration time, and immunological limitations are satisfied.
Can a generic avoid the patent by infusing iron over 20 minutes?
A 20-minute administration generally falls outside the express “about 15 minutes or less” limitation, but infringement analysis must consider the complete claim set, claim construction, labeling, and the actual administration protocol.
Is US 8,895,612 a composition-of-matter patent?
No. Its principal claims are methods of treating iron deficiency using specified iron carbohydrate complexes under specified dosing and administration conditions. It is not, by itself, a composition-only monopoly over ferric carboxymaltose.
References
- United States Patent and Trademark Office. (2014). U.S. Patent No. 8,895,612, Methods for treating iron deficiency.
- U.S. Food and Drug Administration. (2023). Injectafer (ferric carboxymaltose injection) prescribing information. American Regent, Inc.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (n.d.). Product-specific guidance for generic drug development: Ferric carboxymaltose injection and parenteral iron products.
